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Early resuscitation of dengue shock syndrome in
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and safety
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Abstract
Introduction: Dengue shock syndrome (DSS) fluid resuscitation by following the World Health Organization (WHO)
guideline usually required large volumes of Ringer lactate (RL) that might induce secondary fluid overload. Our
objective was to compare the effectiveness of the recommended volume of RL versus a smaller volume of a
hypertonic sodium lactate solution (HSL) in children with DSS. The primary end point was to evaluate the effect
of HSL on endothelial cell inflammation, assessed by soluble vascular cell adhesion molecule-1 (sVCAM-1)
measurements. Secondarily, we considered the effectiveness of HSL in restoring hemodynamic fluid balance,
acid–base status, and sodium and chloride balances, as well as in-hospital survival.
Methods: A prospective randomized single-blind clinical trial including 50 DSS children was conducted in the
Pediatrics Department of Hasan Sadikin Hospital, Bandung, Indonesia. Only pediatric patients (2 to 14 years old)
fulfilling the WHO criteria for DSS and new to resuscitation treatments were eligible. Patients were resuscitated with
either HSL (5 ml/kg/BW in 15 minutes followed by 1 ml/kg/BW/h for 12 hours), or RL (20 ml/kg/BW in 15 minutes
followed by decreasing doses of 10, 7, 5, and 3 ml/kg BW/h for 12 hours).
Results: In total, 50 patients were randomized and included in outcome and adverse-event analysis; 46 patients
(8.2 ± 0.5 years; 24.9 ± 1.9 kg; mean ± SEM) completed the protocol and were fully analyzed (24 and 22 subjects in
the HSL and RL groups, respectively). Baseline (prebolus) data were similar in both groups. Hemodynamic recovery,
plasma expansion, clinical outcome, and survival rate were not significantly different in the two groups, whereas
fluid accumulation was one third lower in the HSL than in the RL group. Moreover, HSL was responsible for a partial
recovery from endothelial dysfunction, as indicated by the significant decrease in sVCAM-1.
Conclusion: Similar hemodynamic shock recovery and plasma expansion were achieved in both groups despite
much lower fluid intake and fluid accumulation in the HSL group.
Trial Registration: ClinicalTrials.gov NCT00966628. Registered 26 August 2009.
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Introduction
Dengue is the most frequent mosquito-borne viral
infection among human beings, with more than 50 million
new infections being projected annually [1]. Although it
resolves spontaneously in most cases, dengue hemorrhagic
fever (DHF) and dengue shock syndrome (DSS) are among
the leading causes of pediatric hospitalization. Mortality
rates from 1% to 5% are frequently reported for DHF/DSS
from centers experienced in fluid resuscitation, but rates
up to 44% have occasionally been reported in cases of
established shock [2].
The major pathophysiologic abnormality responsible
for DHF/DSS is an acute increase in vascular permeability,
leading to plasma leakage from the vascular to the extra-
vascular compartment [2-5], which results in hypovolemia
(biologically characterized by an hemoconcentration), re-
sponsible for a moderate to severe shock. It has been
suggested that the dengue virus induces a swelling of
endothelial cells [3], which may damage the tight-junction
complexes, thus increasing vascular permeability. Usually,
the capillary leakage resolves spontaneously by the sixth
day of illness and is rapidly followed by full recovery.
Microvascular permeability is intrinsically higher among
children than in adults, which may explain why children
are more prone than adults to DSS [4,6].
Endothelial cell inflammation is responsible for a high
expression of VCAM-1 at the cell surface, leading to an
increase in circulating sVCAM-1. It has been proposed
that circulating sVCAM-1 levels may reflect the severity
of the disease [7,8]. Therefore, from a theoretic point of
view, the optimal treatment of DSS should address both
the cause (endothelial dysfunction) and its consequence
(hypovolemia).
Three controlled randomized double-blind trials com-
paring different resuscitation fluids in children with
DHF/DSS failed to demonstrate any benefit of a particu-
lar fluid [9-11]. Comparing four fluids (Ringer lactate,
NaCl 0.9%, dextran 70, and 3% gelatin), Dung et al. [9]
did not find any difference in terms of administered
volume and shock resolution. The same result was ob-
tained in a comparable study with a larger population
[10]. However, it was noted that the early administration
of colloids to the most severely affected subgroup of
patients was beneficial [10]. A randomized double-blind
trial comparing three fluids (Ringer lactate, 6% dextran
70, 6% hydroxyethyl starch) for initial resuscitation of
children with DSS established that isotonic crystalloids
(RL) were as effective as colloids for initial resuscita-
tion of children with moderate shock [11]. Conse-
quently, the WHO recommends that patients with
DSS should benefit from an immediate volume replace-
ment with isotonic crystalloid solutions, followed by
the use of plasma or colloid solutions for profound or
continuing shock [2].
Totilac is a hypertonic lactate-based solution (see Table 1).
It has been shown to be able to restore hemodynamic sta-
tus and improve cardiac performance [12,13]. Moreover,
as compared with other hypertonic crystalloid-based
solutions, lactate can be used as an energy substrate
by various tissues [14]. Finally, the hypertonic lactate-
based solution has been shown to be effective in treating
intracranial hypertension after traumatic brain injury,
with a significantly more-pronounced effect than that
of an equivalent osmotic load of mannitol, suggest-
ing that sodium lactate may have an antiedema effect
per se [15].
Based on this double property (intravenous fluid and
antiedema effect), the present prospective randomized
study was designed to compare the efficacy and safety of
Totilac with RL for resuscitation of DHF/DSS children.
Our hypothesis was that sodium lactate could improve
endothelial cell function and decrease capillary leakage,
thus minimizing fluid overload.
Methods
Fifty children with severe DSS were enrolled in this pro-
spective, randomized, single-blind study (see Figure 1),
conducted in the Pediatrics Department of Hasan Sadikin
Hospital, Bandung, Indonesia, between May 2008 and April
2009. Patients were randomly assigned to RL or hypertonic
sodium lactate solution (HSL) groups. Randomization was
performed independently by using a table of random num-
bers and balanced blocks of four, with sealed opaque enve-
lopes sequentially numbered. The enrollment of patients
was performed by the pediatrician, and the assignment to
intervention, by the study coordinator.
The Ethics Committee of Hasan Sadikin Hospital
had approved this protocol before the study. Informed
consent had also been obtained from the patients’
relatives.
The intervention period ran for the first 12 hours of
treatment and was followed by a 12-hour observation
Table 1 Composition of Ringer lactate (RL) and the
hypertonic sodium lactate (HSL) solution Totilac
Hypertonic sodium
lactate
Ringer lactate
(HSL) (RL)
Content mM g/L mM g/L
Na+ 504.15 11.50 130.5 2.98
K+ 4.02 0.16 4.02 0.16
Ca2+ 1.36 0.050 0.67 0.024
Cl− 6.74 0.24 109.90 3.90
Lactate− 504.15 44.92 28.00 2.49
Total osmolarity (mosm/L) 1,020.42 273
Organic/inorganic osmolarity
(mosm/L)
504.15/516.27 28/245
Somasetia et al. Critical Care 2014, 18:466 Page 2 of 11
http://ccforum.com/content/18/5/466
period (see Figure 2) extended to 48 hours for sVCAM-1
measurement. The outcome, complications, adverse events,
and concomitant treatments were recorded throughout the
entire hospital stay until discharge. Only pediatric patients
(2 to 14 years old) fulfilling the WHO criteria for DSS
and new to resuscitation treatment were eligible. Based
on anamnesis, physical examination, and/or laboratory
tests, patients with another viral or bacterial infection,
severe renal failure (creatinine >180 μM - because of
the high amount of sodium infused), chronic diarrhea
(because it may influence urine output), liver failure
(SGOT and SGPT >20 times normal), severe malnutrition
and diabetes mellitus (because they may change lactate me-
tabolism), and hematologic disorders (because hemostasis
was one studied parameter) were excluded.
Shock management
According to the randomization, eligible patients re-
ceived an initial bolus infusion of either HSL (5 ml/kg
BW) or RL (20 ml/kg BW) for 15 minutes (Figure 2). If
they did not recover from the shock rapidly with the first
bolus, a second loading infusion with the same solution
at the same dosage was infused once again. If the second
treatment failed with a persistent shock, patients received
hydroxyl-ethyl starch (HES, 130/0.40) infusion (20 ml/kg
BW in 15 to 30 minutes) with a maximum dose of 50 ml/
kg BW in 24 hours. Note that the WHO recommends
colloid solutions for profound or continuing shocks,
whereas HES administration was in routine practice, and
concern about its safety was not reported before this study
started.
If the shock was reversed, patients received a mainten-
ance dose of the studied solution for 12 hours: 1 ml/kg
BW/h of HSL, or decreasing doses of 10, 7, 5, and 3 ml/
kg BW/h of RL, based on patients' hemodynamic condi-
tions (heart rate, systolic blood pressure, urine output),
which corresponds to the standard protocol of DSS
management in Hasan Sadikin Hospital according to the
WHO recommendations. If the shock recurred within
the first 12 hours, the studied solution was infused once
again, as in the initial shock management. After the
12th hour (that is, during the follow-up period), both
groups received 3 ml/kg BW/h RL according to the
WHO recommendations. If the shock recurred during
the follow-up period, the standard protocol of DSS
management according to the WHO recommendations
was applied (RL infusion with HES administration if
necessary).
Studied parameters
As markers of hemodynamic status and tissue oxygen-
ation, blood pressure, heart and respiratory rates, Glasgow
Coma Scale score (GCS), body temperature, and urine
output were monitored before (T0) and after 15 and then
Figure 1 Profile of the randomized controlled trial.
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30 minutes, every hour until the hour 6, and then 9, 12,
18, and 24 hours after fluid administration.
Fluid infusion and output were measured and docu-
mented. Laboratory blood/plasma parameters including
hemoglobin, hematocrit, thrombocyte and leukocyte
counts, electrolytes (sodium, potassium, chloride), plasma
osmolality, lactate, glucose, albumin, total protein concen-
trations, SGOT, SGPT, creatinine, venous gas analysis,
prothrombin (PT), activated partial thromboplastin time
(aPTT), fibrinogen levels, and D-dimer were determined
after 0, 6, 12, and 24 hours. sVCAM-1 values were mea-
sured after 0, 24, and 48 hours with the ELISA method
(R&D Systems, Human sVCAM-1/CD106 Quantikine
ELISA Kit, catalog number DVC00). Any adverse events
or serious adverse events that occurred during the study
period were recorded and reported for all included
patients. All concomitant medications and their com-
plement, including dosages, were also documented.
Study end points
The primary end point was the effectiveness of HSL
to decrease endothelial cell inflammation assessed by
sVCAM-1 measurements during the first 48 hours of
DSS. Secondary end points considered the effectiveness of
HSL to restore hemodynamic and tissue-oxygenation
parameters, fluid balance, acid–base status, sodium and
chloride balances, as well as in-hospital survival.
Sample-size determination and statistical analysis
G*Power3.1 [16] was used to calculate the sample size
for a five-repeated-measure ANOVA with an alpha error
of 0.05, a power of 80%, a correlation among repeated
measures of 0.3, and an effect size of 0.3. The theoretical
sample size was n = 21 in each group. We chose to include
25 subjects per group.
Unless otherwise indicated, data are expressed as
mean ± SEM. Qualitative variables were analyzed by
using the Fisher Exact test (Table 2). The effect of DSS
treatment over time was analyzed with ANOVA for repea-
ted measures, indicating the significance of the different
treatments (treatment effect) and evolution (time effect)
(Table 3). Data exhibiting non-normal distribution
were analyzed with nonparametric unpaired (Mann-
Whitney) or paired (Wilcoxon) tests, as indicated in the
legends.
Results
Studied population
The 50 enrolled and randomized patients were included
in outcome and adverse-event analysis (intent-to-treat
analysis). Forty-six patients completed the protocol and
were fully analyzed (24 and 22 subjects in the HSL and
RL groups, respectively) whereas four patients were ex-
cluded: three for incomplete data collection and one for
withdrawal of consent. As shown in Table 2, because of
randomization, the two groups were not different before
Figure 2 Study flow chart.
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treatment in terms of nutritional status, severity of
disease, or baseline parameters.
Initial shock treatment and outcome
As shown in Table 3, no statistical difference was found
in the success rate of a single bolus infusion (P > 0.99) or
in shock recurrence within the first 12 hours (P = 0.14).
The needs of HES administration for initial shock treat-
ment or shock recurrence within the first 12 hours were
not different (P = 0.30 and P = 0.48 for initial and recurrent
shock, respectively). However, HES infusion was more
frequently used during the follow-up period (T12 to T24)
in the HSL group (5 versus 0), leading to a significantly
more frequent total HES administration (intervention and
follow-up periods) in the HSL group (10 versus 1,
P = 0.005).
No difference was noticed regarding the outcome. The
full recovery rate was similar in the two groups (P = 0.70).
Two patients in each group left the hospital on hospital
Table 2 Baseline quantitative data (mean (SEM))
HSL RL
n = 24 n = 22
Age, years 8.7 (0.6) 7.6 (0.7)
Body weight, kg 27.1 (3.0) 22.5 (2.0)
Height, cm 126.7 (4.4) 118.1 (3.8)
Sex ratio (F:M) 11:13 11:11
GCS 14.4 (0.3) 14.8 (0.2)
Systolic pressure, mm Hg (n = 9 + 9) 89.4 (4.7) 86.1 (3.7)
Diastolic pressure, mm Hg (n = 9 + 9) 61.1 (6.5) 65.6 (4.4)
Heart rate, beats/min 133.9 (4.8) 121.7 (3.7)
Respiratory rate, breaths/min 34.4 (2.2) 33.4 (1.7)
Temperature, °C 36.7 (0.2) 36.2 (0.2)
DHF grade III 9 9
DHF grade IV 15 13
Hematocrit, % 41.9 (0.93) 42.4 (1.2)
Hemoglobin, g/dl 14.5 (0.3) 14.7 (0.5)
Leukocyte, mm−3 6,217 (854) 6,000 (755)
Thrombocyte, mm−3 47,042 (7,693) 59,409 (7,421)
pH (venous) 7.40 (0.03) 7.37 (0.02)
pCO2 (venous), mm Hg 24.9 (1.5) 24.8 (1.4)
pO2 (venous), mm Hg, 55.6 (7.2) 66.9 (7.8)
CO3H
− (venous), mM 15.2 (0.9) 13.8 (0.7)
BE (venous), mM −7.6 (1.1) −10.3 (0.9)
Na, mM 129.8 (1.2) 128.1 (0.9)
K, mM 4.36 (0.14) 4.64 (0.17)
Cl, mM 94.3 (1.3) 95.8 (1.1)
Osmolality, mOsm/kg H2O 284.0 (4.6) 275.4 (1.8)
Glucose, mM 6.74 (0.37) 6.11 (0.43)
Lactate, mM 4.71 (0.67) 3.81 (0.85)
Creatinine, mg/dl 0.68 (0.06) 0.55 (0.04)
Albumin, g/L 32.8 (1.6) 34.5 (1.4)
Protein, g/L 59.3 (2.4) 62.2 (2.9)
SGOT μu.L−1 798 (422) 387 (106)
SGPT u/L 283 (158) 119 (28)
PT, seconds 12.0 (0.7) 11.5 (0.7)
aPTT, seconds 42.0 (4.5) 36.6 (2.4)
D-dimer ng/ml 627 (198) 455 (85)
Fibrinogen, mg/L 163.7 (14.6) 154.3 (16.7)
Table 3 Randomization, treatment, and evolution of DSS:
comparison between HSL and RL
Patients included 50
Randomization HSL RL P*
Patients randomized 25 25
Patients withdrawn 1 3 0.60
Patients studied 24 22
Per protocol analysis (n = 46)
Initial shock treatment (number of patients)
One bolus/two boluses 18/6 17/5 >0.99
HES infusions 4 1 0.30
Number of recurrent shocks within the first 12 hours (number of patients)
Yes/No 7/17 2/20 0.14
HES infusions 1 0 0.48
Total HES infusions (24 hours) 10 1 0.005
Concomitant therapies
Blood products
Thrombocytes 1 4 0.18
Cryoprecipitate 0 2 0.22
Fresh frozen plasma 1 3 0.34
Antibiotics 7 4 0.60
Furosemide 3 3 >0.99
Catecholamines 1 1 >0.99
Antipyretic 6 1 0.13
Total colloid (HES + plasma) (24 hours) 11 4 0.06
Intent-to-treat analysis (n = 50)
Outcome
Recovery 22 20 0.70
Forced discharge 2 2 >0.99
Death 1 3 0.60
Adverse events/complications
DIC 3 5 0.70
Encephalopathy 4 3 >0.99
Respiratory distress syndrome 1 0 >0.99
Acute liver failure 0 2 0.47
*Fisher Exact test.
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discharge against medical advice after the intervention
period. One versus three people died in the HSL and RL
groups, respectively (P = 0.60). All four died because of
irreversible/terminal shock and multiorgan failures with
disseminated intravascular coagulation.
Concomitant therapies did not significantly differ
between the two groups (Table 3). However, it could be
underlined that, due to the occurrence of hematologic
disorder, blood products (that is, thrombocytes, cryopre-
cipitate, and fresh frozen plasma) were required for 0ne
and five patients in the HSL and RL groups, respectively
(P = 0.09, Fisher Exact test), corresponding to two and
nine blood products in the HSL and RL groups, re-
spectively. Note that the frequency of use of colloids
(HES + fresh frozen plasma) was not significantly differ-
ent in the two groups.
Comparison of the two fluid regimens on clinical
parameters, intravascular volume expansion, and fluid
balance
As shown in Figure 3, systolic blood pressure had im-
proved very significantly at the end of the bolus infusion
(P < 0.0001) in both groups. This improvement persisted
through the intervention and follow-up periods in
both groups, with no difference between the two groups
(P = 0.90). Hematocrit decreased significantly (P < 0.0001)
in both groups, with no interaction between time and
groups. Note that no patient received red cell packs. The
urinary output rate (not shown) increased immediately after
the beginning of fluid administration (P < 0.0001), with a
more-pronounced effect in the RL group (P = 0.007).
According to the protocol, patients in the RL group
received much more fluid than those in the HSL group.
The difference increased with time during the interven-
tion period, reaching a four- to fivefold higher intake in
the RL group than in the HSL group after 12 hours
(115.9 ± 3.8 versus 26.2 ± 2.9 ml/kg/12 h, for RL and
HSL, respectively, P < 0.0001). During the follow-up period,
changes in fluid intake were parallel, as both groups then
received the same treatment. Cumulative urine output was
slightly but significantly (P = 0.018) higher in the RL group.
However, as shown in Figure 4, the difference in fluid bal-
ance between the two groups was significant (P < 0.0001).
The RL group accumulated 107 ± 7 ml/kg/24 h, whereas
the HSL group accumulated only 35 ± 10 ml/kg/24 h.
Note that Figure 4 takes into account all the fluids infused
(crystalloids, HES, and concomitant therapies, including
fresh frozen plasma). Interestingly, at the end of the inter-
vention period (H12), when the initial shock had already
been successfully treated for a couple of hours in the two
groups, the fluid balance did not differ from zero in the
HSL group (−0.2 ± 0.2 ml/kg/12 h; P = 0.95), whereas it
was positive in the RL group (+75.9 ± 6.0 ml/kg/12 h;
P < 0.0001). In other words, the fluid balance became
positive in the HSL group only after these patients had
been shifted from HSL to RL.
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Figure 3 Effect of treatments on systolic blood pressure and hematocrit. Open circles, RL; solid circles, HSL.
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Comparison of the two fluid regimens on biologic
parameters
The main biologic parameters are shown in Table 4,
before intervention, at hours 6, 12 (end of intervention),
and 24 (end of follow-up period). Venous blood pH
increased with both treatments during the intervention
period, with a higher increase in the HSL than in the RL
group. Increase in bicarbonate also was greater in the
HSL group. No difference between the two treatments
was found on plasma sodium concentration. Plasma po-
tassium concentration decreased over time in both groups,
with a larger decrease in the HSL group. Interestingly,
plasma chloride concentration significantly decreased be-
tween T0 and T12 in the HSL group and then increased
during the follow-up period, whereas it continuously
increased in the RL group. Although the amount of
infused lactate was quite substantial in the HSL group,
blood lactate concentration did not increase in either
the HSL or the RL group. We found no difference
between the two groups for plasma osmolality, blood
glucose concentration, creatinine, albumin, total protein,
or transaminases.
As regards hemostasis, the treatments did not affect
PT or aPTT, while they both brought down fibrinogen.
As seen in Figure 5, D-dimer did not significantly change
(P = 0.7701) after 24 hours in the RL group, whereas it
decreased in the HSL group (P = 0.0468), the difference
between the two groups at the 24th hour remaining insig-
nificant, however (P = 0.2117). sVCAM-1 did not change
in the RL group after 48 hours (P = 0.7089), whereas it
significantly and continuously decreased in the HSL group
(P = 0.0013 between T0 and T24, P = 0.0116 between
T24 and T48, P < 0.0001 between T0 and T48), with
a significant difference between the two groups at the
48th hour (P = 0.0024).
Comparison of the two fluid regimens on sodium and
chloride balance
As seen in Figure 6, cumulative sodium load was posi-
tive in both groups at any time and significantly higher
in the RL than in the HSL group at T6 (P = 0.0027) and
T12 (P = 0.0029). Indeed, despite a lower sodium concen-
tration in RL than in HSL (Table 1), the more-substantial
fluid infusion required led to a superior sodium load in
the RL group.
Chloride cumulative balance significantly increased
during the intervention (P = 0.0006) and the follow-up
period (P = 0.0019) in the RL group. On the contrary, it
significantly decreased (P = 0.0051) during the interven-
tion period in the HSL group. During the follow-up
period (that is, when RL was infused in both groups),
the chloride cumulative balance became positive in the
HSL group (P < 0.0001), but remained significantly lower
than in the RL group (P < 0.0001).
Discussion
It is well acknowledged that the dengue virus can lead to
endothelial cell dysfunction responsible for capillary leak-
age with fluid extravasation from intravascular bed toward
interstitial space. This leads to a severe hypovolemic shock
in the absence of relevant fluid loss such as vomiting or
diarrhea. In the present study, the recovery of such a
severe hypovolemic shock without (first 12 hours) or with
minimal (24 hours) net expansion of body fluids in the
HSL group (see Figure 4) strongly suggests that HSL treat-
ment favored a decrease of capillary leakage, allowing
interstitial fluid to reintegrate the vascular bed.
To the best of our knowledge, all the treatments
applied to DSS are symptomatic as regards shock or
hemorrhagic disorder correction, and etiopathogenic
treatments aiming at limiting the inflammatory response
or virus invasion are reputed to be unsuccessful. The
fact that sVCAM-1 decreased in patients receiving HSL
suggests that this treatment might have improved the
endothelial cell function.
Quite obviously, the plasma-expander effect of HSL
might be related to its hyperosmolarity because a similar
effect has been reported with hypertonic saline [17-19].
However, although HSL is hyperosmolar (see Table 1), it
is less hypertonic than a sodium-chloride solution with
the same osmolarity, because the monocarboxylate car-
rier allows lactate to cross the cellular plasma membrane
[20]. In other words, lactate is expected to leave the
intravascular bed to spread inside the cells. In agreement
with such a property, lactate concentration did not
increase in the HSL group.
Once into the cell, lactate is rapidly metabolized
(mainly in glucose or in CO2 plus H2O), whereas Na
+ is
eliminated in urine. However, to maintain urine electro-
neutrality, negative charges must be eliminated with Na+,
-500
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Figure 4 Effect of treatments on fluid balance. Open circles,
RL; solid circles, HSL.
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including Cl−, which results in a net negative chloride bal-
ance (see Figure 6). Because chloride loss was dramatically
higher than the decrease in plasma chloride concentration
(compare Figure 6 with Table 4), the net negative chloride
balance was done mostly at the expense of intracellular
chloride. Recent data on Na+, K+, and Cl− co-exchange
support a significant role of chloride balance on cell-
volume regulation [21-23]. Hypothesizing that the dengue
virus leads to endothelial cells swelling that in turn in-
creases endothelium permeability because of changes in
the cell shape, we propose that lactate might return the
cell volume back to normal, thus correcting capillary
leakage. Note that a negative chloride balance and a
decrease in cerebral edema have also been reported in
Table 4 Evolution of blood parameters at 0, 6, 12, and 24 hours after initiation of shock treatment expressed as mean
(SEM)
Treatment T0 T6 T12 T24 P treatment P time P interaction
Leukocytes, mm−3 HSL 6,217 (854) 5,600 (566) 6,665 (698) 7,100 (764) 0.862 0.001 0.844
RL 6,000 (755) 5,805 (842) 6,623 (816) 7,864 (1,016)
Thrombocytes, mm−3 HSL 47,042 (7,693) 44,583 (6,102) 40,348 (6,001) 48,773 (5,817) 0.297 0.016 0.529
RL 59,409 (7,421) 48,727 (5,870) 50,455 (6,583) 55,909 (4,867)
pH (venous) HSL 7.40 (0.03) 7.50 (0.01) 7.50 (0.02) 7.46 (0.01) <0.0001 <0.0001 0.100
RL 7.37 (0.02) 7.40 (0.01) 7.41 (0.01) 7.39 (0.01)
CO3H
− (venous), mM HSL 15.20 (0.87) 21.56 (1.04) 26.53 (1.19) 25.18 (0.73) <0.0001 <0.0001 <0.0001
RL 13.76 (0.72) 15.21 (0.86) 16.94 (0.72) 19.35 (0.85)
Na, mM HSL 129.8 (1.2) 129.8 (1.2) 130.0 (1.3) 130.6 (1.3) 0.935 0.013 0.081
RL 128.1 (0.9) 129.0 (1.0) 130.3 (0.8) 132.7 (1.3)
K, mM HSL 4.36 (0.14) 3.42 (0.13) 3.23 (0.11) 3.18 (0.11) <0.0001 <0.0001 0.001
RL 4.64 (0.17) 4.26 (0.10) 4.23 (0.16) 4.28 (0.15)
Cl, mM HSL 94.3 (1.3) 90.5 (1.2) 89.5 (1.5) 92.5 (1.1) <0.0001 0.003 <0.0001
RL 95.8 (1.1) 97.6 (1.0) 99.6 (1.1) 100.9 (0.9)
Osmolality, mOsm/Kg H2O HSL 284.0 (4.6) 277.9 (2.2) 278.5 (2.6) 276.4 (2.2) 0.240 0.416 0.104
RL 275.4 (1.8) 274.2 (2.4) 275.2 (1.5) 279.5 (2.6)
Glucose, mM HSL 6.74 (0.37) 6.56 (0.27) 6.60 (0.39) 5.72 (0.35) 0.003 0.001 0.355
RL 6.11 (0.43) 5.14 (0.27) 5.35 (0.33) 4.85 (0.29)
Lactate, mM HSL 4.71 (0.67) 2.94 (0.41) 2.93 (0.32) 1.65 (0.20) 0.313 <0.0001 0.183
RL 3.81 (0.85) 1.87 (0.30) 2.11 (0.44) 2.24 (0.54)
Creatinine, mg/dl HSL 0.677 (0.063) 0.569 (0.066) 0.631 (0.088) 0.607 (0.105) 0.070 <0.0001 0.552
RL 0.549 (0.039) 0.440 (0.023) 0.466 (0.030) 0.416 (0.023)
Albumin, g/L HSL 32.8 (1.6) 29.5 (1.1) 28.5 (1.1) 26.5 (0.9) 0.695 <0.0001 0.287
RL 34.5 (1.4) 28.5 (0.8) 28.5 (0.7) 27.6 (0.9)
Protein, g/L HSL 59.3 (2.4) 50.7 (2.3) 48.5 (2.6) 48.0 (1.8) 0.264 <0.0001 0.990
RL 62.2 (2.9) 53.1 (1.8) 51.3 (1.3) 50.2 (1.6)
SGOT u/L HSL 798 (422) 870 (383) 765 (373) 503 (191) 0.636 0.776 0.263
RL 387 (106) 512 (229) 631 (363) 656 (355)
SGPT u.L−1 HSL 283 (158) 258 (103) 245 (109) 185 (76) 0.678 0.934 0.267
RL 118 (27) 181 (87) 218 (122) 229 (119)
PT, seconds HSL 12.0 (0.7) 12.2 (0.8) 12.2 (0.6) 11.4 (0.5) 0.443 0.221 0.094
RL 11.5 (0.7) 11.4 (1.0) 13.6 (2.8) 17.8 (4.6)
aPTT, seconds HSL 42.0 (4.5) 49.4 (4.7) 50.6 (4.8) 39.9 (2.3) 0.179 0.386 0.117
RL 36.6 (2.4) 39.9 (2.5) 38.3 (3.4) 44.6 (7.9)
Fibrinogen, mg/L HSL 163.7 (14.6) 123.1 (10.9) 131.7 (11.1) 124.1 (7.2) 0.443 <0.0001 0.734
RL 154.2 (16.7) 117.6 (8.8) 110.5 (7.9) 118.4 (9.6)
Repeated measures ANOVA between HSL and RL: P treatment, effect of treatment; P time, effect of time; P interaction, interaction between treatment and time.
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traumatic brain-injured patients infused with sodium
lactate [15], whereas HSL has been shown to reduce the
number of intracranial hypertensive episodes after severe
traumatic brain injury [24].
From these considerations, it appears that HSL may
affect intra- versus extracellular fluid distribution in at
least two different ways: sodium-related hypertonicity
and electrogenic imbalance corrected by chloride efflux
from intracellular space.
There are several limitations to this study. The rate of
lactate infusion used in this work was based on previous
data indicating an average endogenous rate of lactate
turnover of 10 to 14 mmol/kg/24 h and plasma clearance
of about 10 to 14 ml/kg [25,26], as well as on previous
administration of lactate to patients [12,15]. Note that the
initial bolus infusion of HSL (5 ml/kg BW) was as effective
as the initial bolus infusion of RL (20 ml/kg BW) for the
acute shock management, as indicated by a similar initial
recovery, including the success rate of a single bolus
infusion.
However, the number of patients requiring HES for
the initial shock treatment was higher (although not sig-
nificantly different) in the HSL group. The fluid infusion
rate of HSL after boluses (1 ml/kg/h) or the duration of
the study period (during the first 12 hours) may have
been underestimated for some patients. Indeed, recurrent
shocks were more frequent (although not significantly so)
in the HSL group during the study period (first 12 hours).
Moreover, HES administration was required during the
follow-up period in the HSL group (that is, once sodium
lactate infusion had been stopped). This may suggest that
a higher rate of fluid infusion after boluses (for instance,
2 ml/kg/h) is required, or that the study period should be
extended for some patients. Note, however, that blood
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products were more frequently used in the RL group,
which accounts for a significant volume of perfusion and
may play down the difference in HES use between the two
groups. Indeed, considering the perfusion of colloids (HES
and fresh frozen plasma), no significant difference was
noted between the two groups.
The outcome was similar in the two groups, as were
the complications and the absence of any treatment-
related side effect. We noted a slightly higher mortality
in the RL group as compared with the HSL group, but
this difference was not significant. Indeed, because this
study was not powered to evaluate a beneficial outcome
(but only the physiological consequences of the two
treatments), a large multicentric study would be needed
to do so.
Conclusion
This randomized clinical trial has shown that the use of
hyperosmolar sodium-lactate solutions in the Dengue
shock syndrome allowed the treatment of such a hypo-
volemic shock with minimal fluid accumulation. Besides
the fact that this treatment helped prevent fluid over-
load, the reduction of sVCAM may have contributed to
the resolution of shock. Despite the preliminary nature
of our data, the putative mechanism of action of hyperos-
molar sodium-lactate solution is of sufficient interest to
justify a large-scale clinical trial.
Key messages
 Hyperosmolar sodium-lactate solutions allowed
the correction of dengue shock syndrome with
minimal fluid overload.
 This strongly suggests that hyperosmolar
sodium-lactate favored a decrease of capillary
leakage, allowing interstitial fluid to reintegrate the
vascular bed.
Abbreviations
aPTT: Activated partial thromboplastin time; DHF: Dengue hemorrhagic fever;
DIC: disseminated intravascular coagulation; DSS: Dengue shock syndrome;
GCS: Glasgow coma score; HES: hydroxyl-ethyl starch; HSL: hypertonic
sodium lactate solution; PT: prothrombin time; RL: Ringer lactate; sVCAM-1: soluble
vascular cell adhesion molecule-1; WHO: World Health Organization.
Competing interests
The late Professor Xavier Leverve was a member of the Innogene
International Scientific Board Advisors.
The other authors confirm that they have no commercial or other
associations that might generate a conflict of interest in connection
with the submitted article.
Authors' contributions
DHS participated in the design of the study, carried out the acquisition of
data, and helped to draft the manuscript. TES conceived of the study,
participated in its design and coordination, and helped to draft the
manuscript. AMS participated in the design of the study, carried out the
acquisition of data, and helped to draft the manuscript. PSI participated in
the design of the study, carried out the acquisition of data, and helped to
draft the manuscript. DS participated in the design of the study, carried out
the acquisition of data, and helped to draft the manuscript. HR participated
in the design of the study, performed the statistical analysis, and helped to
draft the manuscript. CI analyzed and interpreted the data, and participated
in the writing of the manuscript. EF analyzed and interpreted the data, and
participated in the writing of the manuscript. XML conceived of the study,
participated in its design and coordination, and helped to draft the
manuscript. All authors, except late Professor XML and late Professor TES,
read and approved the final manuscript. We thank Christophe Cottet for the
English corrections to this manuscript.
Acknowledgements
This study was supported by a grant from Innogene Kalbiotech, Pte. Ltd., 24
Raffles Place 27 – 06 Clifford Centre, Singapore 048621. This support served
for data collection. The funding body played no role in the design of the
study, in the analysis and interpretation of the data, in the writing of the
manuscript, or in the decision to submit the manuscript for publication.
The half-molar sodium-lactate containing solution is patented (WO 2004/
096204 -11/11/04, Gazette 2004/46) and registered (Totilac™).
Author details
1Department of Pediatrics, Padjadjaran University, Bandung, Indonesia.
2Department of Pediatrics, Diponegoro University, Semarang, Indonesia.
3LBFA - INSERM U1055, Joseph-Fourier University, BP 53 38041 Grenoble,
Cedex, France. 4Service de Réanimation, Nice Sophia-Antipolis University,
Nice, France.
Received: 28 January 2014 Accepted: 21 July 2014
References
1. Halstead SB: Dengue. Lancet 2007, 370:1644–1652.
2. The World Health Organization and the Special Programme for Research
and Training in Tropical Diseases (Ed): Dengue guidelines for diagnosis,
treatment and control. Geneva: WHO Library Cataloguing-in-Publication
Data; 2009.
3. Basu A, Chaturvedi UC: Vascular endothelium: the battlefield of dengue
viruses. FEMS Immunol Med Microbiol 2008, 53:287–299.
4. Guzman MG, Kouri G: Dengue: an update. Lancet Infect Dis 2002, 2:33–42.
5. Rajapakse S: Dengue shock. J Emerg Trauma Shock 2011, 4:120–127.
6. Bethell DB, Gamble J, Pham PL, Nguyen MD, Tran TH, Ha TH, Tran TN,
Dong TH, Gartside IB, White NJ, Day NP: Noninvasive measurement of
microvascular leakage in patients with dengue hemorrhagic fever.
Clin Infect Dis 2001, 32:243–253.
7. Koraka P, Murgue B, Deparis X, Van Gorp EC, Setiati TE, Osterhaus AD,
Groen J: Elevation of soluble VCAM-1 plasma levels in children with
acute dengue virus infection of varying severity. J Med Virol 2004,
72:445–450.
8. Murgue B, Cassar O, Deparis X: Plasma concentrations of sVCAM-1 and
severity of dengue infections. J Med Virol 2001, 65:97–104.
9. Dung NM, Day NP, Tam DT, Loan HT, Chau HT, Minh LN, Diet TV,
Bethell DB, Kneen R, Hien TT, White NJ, Farrar JJ: Fluid replacement in
dengue shock syndrome: a randomized, double-blind comparison of
four intravenous-fluid regimens. Clin Infect Dis 1999, 29:787–794.
10. Ngo NT, Cao XT, Kneen R, Wills B, Nguyen VM, Nguyen TQ, Chu VT,
Nguyen TT, Simpson JA, Solomon T, White NJ, Farrar J: Acute management
of dengue shock syndrome: a randomized double-blind comparison
of 4 intravenous fluid regimens in the first hour. Clin Infect Dis 2001,
32:204–213.
11. Wills BA, Nguyen MD, Ha TL, Dong TH, Tran TN, Le TT, Tran VD, Nguyen TH,
Nguyen VC, Stepniewska K, White NJ, Farrar JJ: Comparison of three fluid
solutions for resuscitation in dengue shock syndrome. N Engl J Med 2005,
353:877–889.
12. Leverve XM, Boon C, Hakim T, Anwar M, Siregar E, Mustafa I: Half-molar
sodium-lactate solution has a beneficial effect in patients after coronary
artery bypass grafting. Intensive Care Med 2008, 34:1796–1803.
13. Mustafa I, Roth H, Hanafiah A, Hakim T, Anwar M, Siregar E, Leverve XM:
Effect of cardiopulmonary bypass on lactate metabolism. Intensive Care
Med 2003, 29:1279–1285.
14. Leverve XM, Mustafa I: Lactate: a key metabolite in the intercellular
metabolic interplay. Crit Care 2002, 6:284–285.
Somasetia et al. Critical Care 2014, 18:466 Page 10 of 11
http://ccforum.com/content/18/5/466
15. Ichai C, Armando G, Orban JC, Berthier F, Rami L, Samat-Long C,
Grimaud D, Leverve X: Sodium lactate versus mannitol in the treatment
of intracranial hypertensive episodes in severe traumatic brain-injured
patients. Intensive Care Med 2009, 35:471–479.
16. Faul F, Erdfelder E, Lang AG, Buchner A: G*Power 3: a flexible statistical
power analysis program for the social, behavioral, and biomedical
sciences. Behav Res Methods 2007, 39:175–191.
17. Rahal L, Garrido AG, Cruz RJ Jr, Silva E, Poli-de-Figueiredo LF: Fluid
replacement with hypertonic or isotonic solutions guided by mixed
venous oxygen saturation in experimental hypodynamic sepsis. J Trauma
2009, 67:1205–1212.
18. Shih CC, Chen SJ, Chen A, Wu JY, Liaw WJ, Wu CC: Therapeutic effects of
hypertonic saline on peritonitis-induced septic shock with multiple
organ dysfunction syndrome in rats. Crit Care Med 2008, 36:1864–1872.
19. van Haren FM, Sleigh J, Boerma EC, La Pine M, Bahr M, Pickkers P, van der
Hoeven JG: Hypertonic fluid administration in patients with septic shock:
a prospective randomized controlled pilot study. Shock 2012, 37:268–275.
20. Halestrap AP, Price NT: The proton-linked monocarboxylate transporter
(MCT) family: structure, function and regulation. Biochem J 1999,
343:281–299.
21. Chen H, Sun D: The role of Na-K-Cl co-transporter in cerebral ischemia.
Neurol Res 2005, 27:280–286.
22. Jayakumar AR, Norenberg MD: The Na-K-Cl co-transporter in astrocyte
swelling. Metab Brain Dis 2010, 25:31–38.
23. Jayakumar AR, Panickar KS, Curtis KM, Tong XY, Moriyama M, Norenberg MD:
Na-K-Cl cotransporter-1 in the mechanism of cell swelling in cultured
astrocytes after fluid percussion injury. J Neurochem 2011, 117:437–448.
24. Ichai C, Payen JF, Orban JC, Quintard H, Roth H, Legrand R, Francony G,
Leverve XM: Half-molar sodium lactate infusion to prevent intracranial
hypertensive episodes in severe traumatic brain injured patients: a
randomized controlled trial. Intensive Care Med 2013, 39:1413–1422.
25. Chiolero R, Tappy L, Gillet M, Revelly JP, Roth H, Cayeux C, Schneiter P,
Leverve X: Effect of major hepatectomy on glucose and lactate
metabolism. Ann Surg 1999, 229:505–513.
26. Revelly JP, Tappy L, Martinez A, Bollmann M, Cayeux MC, Berger MM,
Chiolero RL: Lactate and glucose metabolism in severe sepsis and
cardiogenic shock. Crit Care Med 2005, 33:2235–2240.
doi:10.1186/s13054-014-0466-4
Cite this article as: Somasetia et al.: Early resuscitation of dengue shock
syndrome in children with hyperosmolar sodium-lactate: a randomized
single-blind clinical trial of efficacy and safety. Critical Care 2014 18:466.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Somasetia et al. Critical Care 2014, 18:466 Page 11 of 11
http://ccforum.com/content/18/5/466
